Abstract: Individuals with bipolar disorder (BD) have high rates of nonadherence, medical illness, and premature mortality. This analysis reexamined correlates of poor adherence to nonpsychiatric medication in 73 patients with BD and medical comorbidities. The majority was female (74%) and African American (77%) with mean age of 48.08 (SD, 8.04) years, mean BD duration of 28.67 (SD, 10.24) years, mean years of education of 12.01 (SD, 1.87), and mean proportion of days with missed doses in past week of 43.25 (SD, 31.14). Sex, age, education, race, and living alone did not correlate with adherence. More BD medications and more severe psychiatric symptoms correlated with worse adherence. Specifically, poor adherence correlated with the retardation and vegetative factors of Montgomery-Åsberg Depression Rating Scale and affect factor of the Brief Psychiatric Rating Scale. Among poorly adherent patients with BD and medical comorbidities, the number of BD medications, tension/anxiety, and somatic symptoms of depression related to worse nonpsychiatric medication adherence.
I ndividuals with bipolar disorder (BD) have a mortality rate 2 to 3 times that of the general population, with the largest number of deaths being from cardiovascular disease (Birkenaes et al., 2007; Ramsey et al., 2010; Ramsey et al., 2013) . The higher rate of cardiovascular disease is attributed to unhealthy behaviors, such as poor diet, smoking, inactivity, increased risk of social factors such as poverty and homelessness, genetic predisposition, and metabolic adverse effects of psychiatric medication (Birkenaes et al., 2007; Centorrino et al., 2009) . Another important factor impacting health in this population is poor adherence to medication regimens (Busby and Sajatovic, 2010; Sajatovic et al., 2007; Sajatovic et al., 2009; Scott and Pope, 2002a) . The data are sparse regarding the extent and correlates of poor adherence to nonpsychiatric medications in this population. However, the extensive literature on psychiatric nonadherence in patients with BD and poor adherence to medications for physical health conditions in the general population may provide insight into the barriers for adherence to nonpsychiatric medication for individuals with BD.
Correlates of poor adherence to psychiatric medication in individuals with BD include denial of illness, symptom severity, cognitive impairment, adverse effects, lack of illness knowledge, disorganized home environment, lack of social support, problems accessing treatment, and comorbid substance abuse (Clatworthy et al., 2007; Hou et al., 2010; Levin et al., 2015; Pompili et al., 2013; Sajatovic et al., 2011; Sajatovic et al., 2015) . Recent reviews also identify several sociodemographic correlates of poor adherence to BD medications. These include younger age, female sex, lower education, family history of BD, nonwhite race, nonmarried, living in a nonurban region, homelessness, financial hardship, and unemployment (Leclerc et al., 2013; Pompili et al., 2013) .
Factors associated with poorer adherence to nonpsychiatric medication in the general population include more medical comorbidities, number of medications prescribed, higher medication cost, less follow-up care, lack of trust and communication between patient and provider, complexity of treatment, lack of social support, cognitive impairment, negative feelings toward medication, and substance use (Rolnick et al., 2013; Tamblyn et al., 2014; Wheeler et al., 2014) . In addition, a number of sociodemographic correlates of poor adherence to medical therapy have been identified in the general population and include being female, nonwhite race, being younger, having less education, having lower income, living alone, being nonmarried, and having an unstable living environment (Rolnick et al., 2013; Wheeler et al., 2014) . There is also extensive evidence that psychological factors, such as depression, are associated with a decline in adherence to medications for various chronic medical conditions (Eze-Nliam et al., 2010; King et al., 2012; Osborn and Egede, 2012; Wheeler et al., 2014) .
Recently, we reported that there is no significant correlation between psychiatric and nonpsychiatric medication adherence in patients with BD, that poor adherence to nonpsychiatric medication, while still a significant problem, is lower than to BD agents, and that there is a significant correlation between general psychiatric symptoms as measured by the Brief Psychiatric Rating Scale (BPRS) and poor adherence to nonpsychiatric medication (Levin et al., 2016) . The current study set out to explore in greater detail the sociodemographic variables and specific cluster of psychiatric symptoms associated with poor adherence to nonpsychiatric medication in individuals with BD.
It was hypothesized that age (younger), sex (female), lower education, living alone, nonwhite race, BD type I, and taking more medications would be associated with worse nonpsychiatric medication adherence. It was also hypothesized that particular psychiatric symptoms would differentially positively correlate with poor nonpsychiatric medication adherence. Specifically, it was hypothesized that the resistance, positive symptoms, affect, and negative symptoms factors, but not the activation factor, of the BPRS would correlate with poor nonpsychiatric medication adherence. Furthermore, it was hypothesized that the vegetative and retardation factors, but not the dysphoria factor, of the Montgomery-Åsberg Depression Rating Scale (MADRS) would correlate with poor nonpsychiatric medication adherence.
METHODS

Participants
The demographic, clinical, and health characteristics of the sample of 73 patients with BD and medical comorbidities are summarized in Table 1 . Participants had a mean age of 48.08 (SD, 8.04 ) and mean years of education of 12.01 (SD, 1.87). The majority of the sample was female (74.0%), African American (76.7%), unable to work because of a disabling condition (61.6%), and met criteria for BD type I (74.3%). The mean age of BD onset was 19.68 (SD, 9.27) years, and the mean number of years with BD was 28.55 (SD, 10.21). Mean MADRS and BPRS scores fell in the moderate range with 19.90 (SD, 8.82) and 36.79 (SD, 7.19) for MADRS and BPRS, respectively. Average lifetime number of psychiatric hospitalizations was 6.15 (SD, 9.85).
Materials
Tablets Routine Questionnaire (TRQ), a self-report measure, identifies levels of nonadherence for the past 7 and past 30 days Pope, 2002a, 2002b) . Tablets Routine Questionnaire has been shown to correlate highly with lithium levels (Scott and Pope, 2002a) . The percentage of days with missed doses in the past week was assessed for each prescribed foundational oral medication for the treatment of BD. For individuals who were on 1 or more foundational medications, an average was calculated in order to gather information on the full BD treatment regimen. We did not measure the level of adherence to antidepressant drugs as they are often prescribed sporadically to target acute symptoms and are not considered to be maintenance medication for BD. For individuals who reported being prescribed nonpsychiatric medication, the percentage of days with missed doses was calculated for each medication separately, and then an average TRQ for all nonpsychiatric medications was then calculated. Higher TRQ scores are a reflection of worse medication adherence.
The BPRS measures global psychopathology (Overall and Gorham, 1962) . Total scores on the BPRS range from 18 to 126, with higher scores indicating more severe psychiatric symptoms. We utilized a robust 5-factor model identified by a meta-analysis of 26 factor analytical studies with a combined sample of 17,620 participants (Shafer, 2005) . The 5 factors include affect, positive symptoms, negative symptoms, resistance, and activation (Table 2) .
The MADRS measures depression symptoms (Montgomery and Åsberg, 1979) . Total scores on MADRS range from 0 to 60, with higher scores indicating more severe depression. Given the multidimensional nature of depression, several studies examined the factor analytical structure of the MADRS. The most robust model, accounting for 61% of the total variance, was that of a 3-factor solution (Suzuki et al., 2005) . The 3 factors include dysphoria, retardation, and vegetative symptoms (Table 2) .
Data on comorbid medical conditions were collected based on the self-report version of the Charlson Comorbidity Index (CCI) (Charlson et al., 1987; Chaudhry et al., 2005) . The CCI summary score is composed of the presence of 10 medical conditions including respiratory diseases, rheumatologic diseases, cancer, diabetes, digestive problems, heart trouble, human immunodeficiency virus or AIDS, kidney disease, liver disease, and stroke. While the original CCI includes dementia, it was excluded from the self-report version given that those with dementia would not be able to provide informed consent. Each disease category is assigned a weight that represents mortality risk, with lower scores indicating lower risk. Given the high risk of cardiovascular disease in this population, self-reported adherence to antihypertensives, cholesterol-lowering agents, and diabetes medications were calculated separately. Self-report data were also gathered via structured interview to identify the presence or absence of hypertension, hyperlipidemia, diabetes, and smoking; to identify the number of daily cigarettes; and to calculate body mass index (BMI). Obesity was defined as having a BMI of 30 kg/m 2 or greater.
Procedure
These data are part of a larger National Institute of Mental Health-funded randomized controlled trial testing a psychosocial intervention intended to promote BD medication adherence versus an educational control in poorly adherent individuals with BD. Study inclusion criteria included having either type I or type II BD as confirmed by SCID (Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Axis I Disorders) (First et al., 2002 ), or in rare cases when a participant could not provide complete information on the SCID (n = 3), the diagnosis was confirmed with their provider, BD for at least 2 years' duration, treatment with at least 1 evidence-based medication to stabilize mood for at least 6 months (lithium, anticonvulsant, or antipsychotic mood stabilizer), and 20% or more of days with missed doses for current BD medication treatment for either the past week or past month as measured by the Tablets Routine Questionnaire (Harvey, 1991) . Past week TRQ was utilized as recall for shorter periods is likely to be more accurate. Past month TRQ was utilized to capture individuals who are adherent for relatively short periods of time but may have more difficulty adhering for longer periods of time. The 20% cutoff was chosen based on the expert consensus guidelines on adherence in patients with serious mental illness (Velligan et al., 2009) . Only those patients reporting a comorbid medical condition on the CCI were included in the analysis. Tablets Routine Questionnaire was completed for any medication that participants considered to be nonpsychiatric based on patient self-report. Study inclusion criteria were purposely broad in order to be generalizable to real-world patients with BD. Only individuals who were unable to participate in study procedures, unable/unwilling to provide informed consent, and those at immediate risk of harm to self or others were excluded. In the current descriptive study, the data analyses utilized screening and baseline data only and did not analyze intervention effects.
Data Analysis
Independent-samples t-tests were run to identify differences between dichotomous demographic variables including sex, living alone, race, and BD type and self-reported average past week TRQ for all nonpsychiatric medications. Spearman ρ correlational analyses were then run between continuous demographic variables including age, number of medications for BD, number of medications for nonpsychiatric medical conditions, and years of education with average past week TRQ for all nonpsychiatric medications. Nonparametric correlation analyses were then run to determine the relationship between continuous variables including symptom severity (MADRS and BPRS), CCI, and self-reported average past week TRQ for nonpsychiatric medications. Factors of the MADRS and BRPS were then correlated with past week nonadherence for psychiatric medications for the whole sample and for African Americans and females separately. All statistical analyses were performed using IBM SPSS Statistics 22 (International Business Machines Corp, Armonk, NY).
The study was approved by the local institutional review board, and all study participants provided written informed consent. Data were collected between October 2012 and June 2015. Table 1 , the most prevalent health problems in this sample of individuals with BD were hypertension (60.3%), rheumatologic diseases (57.5%), hyperlipidemia (47.1%), respiratory diseases (41.1%), and diabetes (31.5%). Seventy-five percent of the sample (n = 50) were smokers with an average of 10.58 (SD, 7.67) cigarettes smoked daily, 72% had a lifetime prevalence of alcohol abuse or dependence, and 74% had a lifetime prevalence of drug abuse or dependence. The average BMI (n = 64) was 33.20 (SD, 8.23 Independent-samples t tests with demographic variables including sex (t 71 = −1.01, p > 0.05), race (African American vs. Caucasian) (t 71 = 0.43, p > 0.05), and BD type (type I vs. type II) (t 68 = 1.62, p = 0.110), being the independent variables, and average past week nonpsychiatric medication TRQ, being the dependent variable, did not produce any significant findings. One-tailed nonparametric correlation analyses between continuous demographic variables and average past week TRQ for all nonpsychiatric medications yielded no significant correlation for age (rs 73 = −0.09, p > 0.05), years of education (rs 72 = 0.05, p > 0.05), the CCI (rs 73 = −0.09, p > 0.05), or number of nonpsychiatric medications prescribed (rs 73 = −0.12, p > 0.05). There was a significant correlation for number of foundational medications for BD prescribed and average past week TRQ for all nonpsychiatric medication (rs 73 = 0.20, p < 0.05) such that more medications for BD related to higher TRQ for nonpsychiatric medication.
RESULTS
As presented in
According to 1-tailed nonparametric correlation analyses, there was a significant positive correlation between MADRS and average past week TRQ for nonpsychiatric medication (rs 73 = 0.28, p < 0.01), as well as for BPRS and average past week TRQ for nonpsychiatric medication (rs 73 = 0.29, p < 0.01) such that more severe BD symptoms were associated with worse adherence to nonpsychiatric medication.
One-tailed Spearman ρ correlations between TRQ for nonpsychiatric medication and factors of the MADRS and BPRS are presented in Table 3 . When examining specific factors of the MADRS, TRQ for nonpsychiatric medication was correlated with the retardation (rs 73 = 0.30, p < 0.01) and vegetative factors (rs 73 = 0.27, p < 0.05) but not with the dysphoria factor (rs 73 = 0.08, p > 0.05). When looking at specific factors of the BPRS, TRQ for nonpsychiatric medication was correlated with the affect factor (rs 73 = 0.26, p < 0.05), and there was a trend with the activation factor (rs 73 = 0.17, p = 0.07) but not with positive symptoms (rs 73 = 0.02, p > 0.05), negative symptoms (rs 73 = 0.09, p > 0.05), or resistance (rs 64 = 0.05, p > 0.05).
Given the fact that the literature notes that race and sex may be related to adherence status (Leclerc et al., 2013; Pompili et al., 2013) , we examined African Americans and females separately. When examining only African Americans, only the retardation factor (rs 56 = 0.24, p < 0.05) of the MADRS and the affect factor (rs 56 = 0.25, p < 0.05) of the BPRS were significantly correlated with past week TRQ for nonpsychiatric medication. When examining only females, both the retardation factor (rs 54 = 0.33, p < 0.01) and the vegetative factor (rs 54 = 0.30, p < 0.05) of the MADRS and the affect factor of (rs 54 = 0.27, p < 0.05) of the BPRS were significantly correlated with past week TRQ for nonpsychiatric medication.
DISCUSSION
The aim of the current study was to examine the sociodemographic variables and specific cluster of psychiatric symptoms associated with poor adherence to nonpsychiatric medication in individuals with BD and medical comorbidities known to be poorly adherent to medications for BD. The findings show that such individuals are more adherent with medications for physical health compared with BD drugs. In addition, being on a larger number of BD medications and having more severe BD symptoms are associated with worse adherence to prescribed medications for physical illness. Contrary to our initial hypothesis, many of the demographic variables that are associated in the literature with either poor adherence to psychiatric medications or nonpsychiatric medication in the general population did not turn out to be significant in our sample of nonadherent patients with BD. Namely, age, education, living alone, and race did not relate to poor adherence to nonpsychiatric medication. It is possible that there may not have been enough power to detect significant findings, particularly for race and living alone, given that the sample of whites was relatively small, and the majority of the sample lived alone. On the other hand, the nonsignificant findings for sex may reflect inconsistencies in the adherence literature, with some studies reporting worse adherence in men (Colom et al., 2005; González-Pinto et al., 2010) , others reporting worse adherence in women (Colom et al., 2000; Sajatovic et al., 2011) , and still others reporting that sex is not correlated to medication adherence (Belzeaux et al., 2013; Gianfrancesco et al., 2006) .
The finding that taking more medications for BD is associated with worse nonpsychiatric medication adherence is consistent with the literature, suggesting that simpler medication regimens are associated with better adherence (de Vries et al., 2014; Ingersoll and Cohen, 2008) . It is known that individuals with BD have cognitive impairment even in euthymic states (Depp et al., 2014) , and it is possible that having fewer medications to remember to take may be easier for individuals who are required to take prescribed medication for physical health conditions. Furthermore, a larger number of medications may be a reflection of increased severity of illness. The finding that more severe BD symptoms are associated with worse adherence has also been reported by others (Barraco et al., 2012; Leclerc et al., 2013; Sajatovic et al., 2015) and does not seem surprising given the likelihood that symptoms of both depressive episodes such as lack of motivation and symptoms of manic episodes including distractibility and lack of focus could both impede an individual's ability to take medications on a regular basis.
Our findings of significant correlations between specific psychiatric symptoms and poor adherence to nonpsychiatric medication could help inform future approaches to enhance adherence among people with BD. For depression, our results suggest that it is not the feeling of sadness or negative thoughts that relate to poor adherence but rather the physiological manifestations of depression including reduced appetite and sleep and inner tension as well as lassitude, inability to feel, apparent sadness, and difficulty concentrating. With regard to the factors of the BPRS associated with nonpsychiatric medication adherence, it is not hostility and uncooperativeness, making up the resistance factor as we predicted, but rather anxiety, guilt, depressed mood, and somatic concern, as well as a trend suggesting that excitement and tension play a role. Taking our findings collectively, specific BD symptoms that seem to be most strongly associated with poor nonpsychiatric medication adherence are inner tension/anxiety and the somatic symptoms of depression. Perhaps care approaches need to target and specifically address factors that can help individuals with these problems in order to help individuals adhere to medications more effectively. For example, the individual with anxiety might benefit from targeted behavioral interventions that can help reduce anxiety, whereas individuals with pervasive vegetative symptoms could potentially benefit from approaches that make it easier to remember to access and take medications, such as technology-facilitated prompts or long-acting drug formulations that require less frequent administration.
In African Americans, symptoms including lassitude, inability to feel, apparent sadness, difficulty concentrating, anxiety, guilt, depressed mood, and somatic concern related to poor nonpsychiatric medication adherence, whereas for females, in addition to these cluster of symptoms, vegetative symptoms of depression also related to poor nonpsychiatric medication adherence. The fact that different sociodemographic groups evidence differences in correlates to medication adherence suggests that interventions to improve illness self-management including adherence should be tailored to specific groups.
Another finding that speaks to the question of illness selfmanagement is that there is not always an association between taking one type of medication and another. This can be seen in both the finding that the proportion of doses missed of psychiatric medications is not associated with the proportion missed for nonpsychiatric medications and the finding that there is no relationship between patterns of adherence with diabetes medications compared with either cholesterol-lowering agents or antihypertensives. These results suggest that an important part of improving illness self-management will be to address knowledge about specific chronic illnesses, psychiatric and medical and to identify and target barriers to adherence to specific types of medications.
There are a number of limitations to the current study that may impact the generalizability of the results. First, the sample was made up largely of African American females. Furthermore, given that the sample was recruited for poor adherence to psychiatric medications, the correlates of poor nonpsychiatric adherence may be different than in patients with BD who are adherent to their BD medications. Also, certain sociodemographic groups had relatively small samples, and thus, the nonsignificant results may reflect a lack of power to detect differences between groups. In addition, the results are based solely on self-reported nonadherence, which may lack reliability given the tendency for people to overestimate nonadherence. In future studies, it will be important to include at least 1 other method to measure adherence, such as pill counts or electronic monitoring devices. It should be noted, however, that because these individuals did acknowledge poor adherence to their psychiatric medication, they may have been less likely to inflate adherence behavior overall. Finally, given that the determination for nonpsychiatric medications was based on participant self-report, it is possible that a psychiatric medication was prescribed for a nonpsychiatric use (such as sleep) yet could have psychotropic effects. Furthermore, it is 
